A High-Throughput, Multi-Index Isothermal Amplification Platform for Rapid Detection of 19 Types of Common Respiratory Viruses Including SARS-CoV-2. (October 2020)

• Record Type: Journal Article
• Authors: Xing, Wanli; Liu, Yingying; Wang, Huili; Li, Shanglin; Lin, Yongping; Chen, Lei; Zhao, Yan; Chao, Shuang; Huang, Xiaolan; Ge, Shaolin; Deng, Tao; Zhao, Tian; Li, Baolian; Wang, Hanbo; Wang, Lei; Song, Yunpeng; Jin, Ronghua; He, Jianxing; Zhao, Xiuying; Liu, Peng; Li, Weimin; Cheng, Jing
• Is Part Of: Engineering. Volume 6:Number 10(2020)
• Page Start: 1130
• Page End: 1140
• Publication Date: 2020-10
• Subjects: Coronavirus disease 2019 -- Severe acute respiratory syndrome coronavirus 2 -- Microfluidics -- Nucleic acid testing -- Isothermal amplification; Engineering -- Periodicals; Engineering -- China -- Periodicals; 620.005
• DOI: 10.1016/j.eng.2020.07.015
• Languages: English
• ISSNs: 2095-8099

Abstract

Abstract: Fast and accurate diagnosis and the immediate isolation of patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are regarded as the most effective measures to restrain the coronavirus disease 2019 (COVID-19) pandemic. Here, we present a high-throughput, multi-index nucleic acid isothermal amplification analyzer (RTisochip™-W) employing a centrifugal microfluidic chip to detect 19 common respiratory viruses, including SARS-CoV-2, from 16 samples in a single run within 90 min. The limits of detection of all the viruses analyzed by the RTisochip™-W system were equal to or less than 50 copies·μL −1, which is comparable to those of conventional reverse transcription polymerase chain reaction. We also demonstrate that the RTisochip™-W system possesses the advantages of good repeatability, strong robustness, and high specificity. Finally, we analyzed 201 cases of preclinical samples, 14 cases of COVID-19-positive samples, 25 cases of clinically diagnosed samples, and 614 cases of clinical samples from patients or suspected patients with respiratory tract infections using the RTisochip™-W system. The test results matched the referenced results well and reflected the epidemic characteristics of the respiratory infectious diseases. The coincidence rate of the RTisochip™-W with the referenced kits was 98.15% for the detection of SARS-CoV-2. Based on these extensive trials, we believe that the RTisochip™-W system provides a powerful platform for fighting the COVID-19 pandemic.